Korro Bio, Inc. (NASDAQ:KRRO) Stock Now Rated “Buy” by Wall Street Analysts

Korro Bio, Inc. (NASDAQ:KRRO – Get Free Report) has received an average recommendation of “Buy” from the ten ratings firms that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, six have issued a buy rating and three have issued a strong buy rating on the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $17.29.

Several equities analysts recently weighed in on KRRO shares. Jefferies Financial Group set a $15.00 target price on shares of Korro Bio in a report on Tuesday, October 6th. Wall Street Zen upgraded Korro Bio from a “sell” rating to a “hold” rating in a report on Saturday, November 7th. HC Wainwright reiterated a “buy” rating and issued a $15.00 price target on shares of Korro Bio in a report on Tuesday, October 6th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Korro Bio in a research report on Friday, October 2nd.

Get Our Latest Research Report on KRRO

Insider Buying and Selling

In other Korro Bio news, SVP Oliver Dolan sold 7,347 shares of the company’s stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $13.51, for a total value of $99,257.97. Following the completion of the transaction, the senior vice president owned 16,252 shares in the company, valued at $219,564.52. This represents a 31.13% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jean Formela sold 40,045 shares of Korro Bio stock in a transaction that occurred on Thursday, November 12th. The shares were sold at an average price of $14.30, for a total transaction of $572,643.50. Following the sale, the director owned 121,219 shares in the company, valued at $1,733,431.70. This represents a 24.83% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have purchased 79,809 shares of company stock valued at $884,919 and have sold 102,758 shares valued at $1,475,724. 4.80% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Korro Bio

A number of institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new stake in shares of Korro Bio during the second quarter valued at about $10,776,000. Affinity Asset Advisors LLC acquired a new position in shares of Korro Bio in the first quarter worth about $8,002,000. Nantahala Capital Management LLC boosted its holdings in Korro Bio by 3.1% in the third quarter. Nantahala Capital Management LLC now owns 680,246 shares of the company’s stock valued at $6,741,000 after purchasing an additional 20,210 shares during the last quarter. ADAR1 Capital Management LLC purchased a new position in Korro Bio in the second quarter valued at about $7,118,000. Finally, Renaissance Technologies LLC boosted its holdings in Korro Bio by 81.9% in the first quarter. Renaissance Technologies LLC now owns 136,227 shares of the company’s stock valued at $1,542,000 after purchasing an additional 61,327 shares during the last quarter. Institutional investors and hedge funds own 13.18% of the company’s stock.

Korro Bio Stock Down 4.9%

Shares of KRRO stock traded down $0.70 on Tuesday, reaching $13.61. 78,960 shares of the stock were exchanged, compared to its average volume of 230,519. The stock has a market cap of $186.87 million, a P/E ratio of -1.50 and a beta of 3.23. The firm has a 50 day moving average of $11.86 and a two-hundred day moving average of $12.16. Korro Bio has a 1-year low of $5.20 and a 1-year high of $17.35.

Korro Bio (NASDAQ:KRRO – Get Free Report) last issued its earnings results on Thursday, November 5th. The company reported ($0.98) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.14) by $0.16. On average, equities research analysts predict that Korro Bio will post -4.45 EPS for the current fiscal year.

About Korro Bio

(Get Free Report)

Korro Bio is a clinical-stage biotechnology company headquartered in Cambridge, Massachusetts. It develops RNA-editing medicines intended to address genetic diseases by changing specific RNA sequences rather than altering a patient’s DNA. The company’s OPERA platform uses oligonucleotides to direct the body’s naturally occurring ADAR enzymes to edit targeted RNA. Korro has developed KRRO-110, an investigational candidate designed to correct a disease-associated RNA change linked to alpha-1 antitrypsin deficiency.

Featured Stories

Analyst Recommendations for Korro Bio (NASDAQ:KRRO)

Receive News & Ratings for Korro Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Korro Bio and related companies with MarketBeat.com's FREE daily email newsletter.